SCHEMBL6626382

SCHEMBL6626382

CC(C)[C@H](NC(=O)[C@@H]1CCCN2C(=O)CC[C@H](NC(=O)c3ccco3)C(=O)N12)C(=O)CSc1nc2ccccc2s1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 9/20 0.44
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
HSD17B10 Q99714 1/20 0.42
IL1B P01584 2/20 0.42
CASP3 P42574 2/20 0.41
CASP8 Q14790 2/20 0.41
MME P08473 1/20 0.40
ACE P12821 1/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LCK P06239 4/20 0.39
CCR1 P32246 2/20 0.38
CCR3 P51677 2/20 0.38
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6627597 1.00 CASP1 (0.44) CASP1ALDH1A1MAPTHSD17B10IL1B
SCHEMBL6629019 0.89 CASP1 (0.43) CASP1ALDH1A1MAPTIL1BMME
SCHEMBL7086596 0.89 CASP1 (0.43) CASP1ALDH1A1MAPTIL1BMME
SCHEMBL7087143 0.86 CASP1 (0.45) CASP1IL1BCASP3CASP8MME
SCHEMBL6627273 0.85 CASP1 (0.46) CASP1ALDH1A1MAPTIL1BCASP3
SCHEMBL6631474 0.85 CASP1 (0.46) CASP1ALDH1A1MAPTIL1BCASP3
SCHEMBL6628214 0.85 CASP1 (0.40) CASP1ALDH1A1MAPTIL1BCASP3
SCHEMBL6628216 0.85 CASP1 (0.40) CASP1ALDH1A1MAPTIL1BCASP3
SCHEMBL6627592 0.83 CASP1 (0.41) CASP1IL1BMMEACELCK
SCHEMBL6627596 0.83 CASP1 (0.41) CASP1IL1BMMEACELCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1246824-B1 CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AVENTIS PHARMA SA (FR) 2004-06-09 EP claimed
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof AVENTIS PHARMA S.A. (FR) 2003-05-29 US claimed
EP-0892797-A4 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL MYERS SQUIBB CO (US) 2004-10-20 EP disclosed
EP-1246824-B1 CARBOXAMIDE DIAZEPIN DERIVATIVES, PREPARATION METHOD, USE AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF AVENTIS PHARMA SA (FR) 2004-06-09 EP disclosed
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof AVENTIS PHARMA S.A. (FR) 2003-05-29 US disclosed
EP-0892797-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1999-01-27 EP disclosed
WO-1997030992-A1 INHIBITORS OF FARNESYL PROTEIN TRANSFERASE BRISTOL-MYERS SQUIBB COMPANY (US) 1997-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100550-A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof HRH4, HRH3, HRH2 CASP1 2506/4885ALDH1A1 3225/4885MAPT 4385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.